Literature DB >> 15793673

[Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome and acral ulcerations].

G Riemekasten1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793673     DOI： 10.1007/s00393-005-0692-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  7 in total

Review 1.  Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.

Authors:  C P Denton; K Howell; R J Stratton; C M Black
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

3.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

4.  Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon.

Authors:  Stephan Rosenkranz; Frank Diet; Thomas Karasch; Julia Weihrauch; Klaus Wassermann; Erland Erdmann
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

5.  Functional vascular disorders: treatment with pentoxifylline.

Authors:  M Neirotti; F Longo; M Molaschi; C Macchione; L Pernigotti
Journal:  Angiology       Date:  1987-08       Impact factor: 3.619

6.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

Authors:  A E Thompson; B Shea; V Welch; D Fenlon; J E Pope
Journal:  Arthritis Rheum       Date:  2001-08

7.  Treatment of Raynaud's phenomenon with captopril.

Authors:  S Tosi; A Marchesoni; K Messina; C Bellintani; G Sironi; C Faravelli
Journal:  Drugs Exp Clin Res       Date:  1987
  7 in total
  3 in total

1.  [Recommendations of the DGRh on the therapy of Raynaud Syndrome (Zeitschrift für Rheumatologie, vol 64, March 2005) ].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

3.  [Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy].

Authors:  H Becker; C Sunderkoetter; P Willeke; W Domschke; M Gaubitz; M Mohr
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.